Cancer Program

The next big questions in cancer research.

Loi S, Settleman J, Joyce JA, et al. The next big questions in cancer research. Cell. 2023;186(8):1523-1527. doi:10.1016/j.cell.2023.01.037Google Scholar DOI PubMed

Targeting TBK1 to overcome resistance to cancer immunotherapy.

Sun Y, Revach OY, Anderson S, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023. doi:10.1038/s41586-023-05704-6Google Scholar DOI PubMed

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.

Dubrot J, Du PP, Lane-Reticker SK, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495-1506. doi:10.1038/s41590-022-01315-xGoogle Scholar DOI PubMed

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.

Bondeson DP, Paolella BR, Asfaw A, et al. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022. doi:10.1038/s43018-022-00360-7Google Scholar DOI PubMed

Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer.

Ouspenskaia T, Law T, Clauser KR, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209-217. doi:10.1038/s41587-021-01021-3Google Scholar DOI PubMed

PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.

Khadka P, Reitman ZJ, Lu S, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022;13(1):604. doi:10.1038/s41467-022-28198-8Google Scholar DOI PubMed

An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.

Lin S, Larrue C, Scheidegger NK, et al. An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discov. 2022;12(2):432-449. doi:10.1158/2159-8290.CD-20-1851Google Scholar DOI PubMed

Somatic and germline genomic alterations in very young women with breast cancer.

Waks AG, Kim D, Jain E, et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-21-2572Google Scholar DOI PubMed

Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma.

Labaki C, Bakouny Z, Sonpavde G, Choueiri TK, Van Allen EM. Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. Eur Urol Oncol. 2022. doi:10.1016/j.euo.2022.01.004Google Scholar DOI PubMed

Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.

Stover EH, Oh C, Keskula P, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022. doi:10.1002/pros.24305Google Scholar DOI PubMed